A practical reference on synthetic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-26. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
稳定性主要由水解与氧化两条路径支配。肽键在中性或弱酸性条件下相对稳定，遇到强碱或长时间高温则明显断裂；甲硫氨酸侧链容易被氧化成亚砜，使主峰前移并拉低实际含量。金属离子、光照和反复冻融会进一步促进降解或聚集。冻干粉在低温避光条件下可存放较长时间，配制后的水溶液通常需要冷藏并尽快用完。
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.
Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
=== EC 1.4.1 With NAD+ or NADP+ as acceptor === EC 1.4.1.1: alanine dehydrogenase EC 1.4.1.2: glutamate dehydrogenase EC 1.4.1.3: glutamate dehydrogenase (NAD(P)+) EC 1.4.1.4: glutamate dehydrogenase (NADP+) EC 1.4.1.5: L-amino-acid dehydrogenase EC 1.4.1.6: deleted, Now included with EC 1.21.4.1, D-proline reductase (dithiol) EC 1.4.1.7: serine 2-dehydrogenase EC 1.4.1.8: valine dehydrogenase (NADP+) EC 1.4.1.9: leucine dehydrogenase EC 1.4.1.10: glycine dehydrogenase EC 1.4.1.11: L-erythro-3,5-diaminohexanoate dehydrogenase EC 1.4.1.12: 2,4-diaminopentanoate dehydrogenase EC 1.4.1.13: glutamate synthase (NADPH) EC 1.4.1.14: glutamate synthase (NADH) EC 1.4.1.15: lysine dehydrogenase EC 1.4.1.16: diaminopimelate dehydrogenase EC 1.4.1.17: N-methylalanine dehydrogenase EC 1.4.1.18: lysine 6-dehydrogenase EC 1.4.1.19: tryptophan dehydrogenase EC 1.4.1.20: phenylalanine dehydrogenase EC 1.4.1.21: aspartate dehydrogenase EC 1.4.1.22: there is no overall consumption of NAD+ during the reaction. As a result, transfer of the enzyme from EC 4.3.1.12 was not necessary and EC 1.4.1.22 was withdrawn before being made official EC 1.4.1.23: valine dehydrogenase (NAD+) EC 1.4.1.24: 3-dehydroquinate synthase II EC 1.4.1.25: L-arginine dehydrogenase EC 1.4.1.26: 2,4-diaminopentanoate dehydrogenase (NAD+) EC 1.4.1.27: glycine cleavage system
These included statements that God emits a cosmic broadcast of electromagnetic waves that living creatures can receive when their neural networks are enabled by DMT; that adding DMT allows people to see otherwise invisible spirits and guardian angels; that schizophrenia and autism result from an over-abundance of bioavailable DMT and should be unified under the term “Autiphrenia,” with those affected described as geniuses created to lead humanity; that vaporizing DMT had cured his brain cancer; that staring at the sun promotes DMT production in the pineal gland; and that DMT could cure other diseases. He invited cancer patients to his ranch in the Lake View Terrace area of Los Angeles to try the substance. In a video recorded after the cancer claim was questioned, Cantelmo stated that he had never had any form of cancer and that the reference was metaphorical, describing atheism as the “worst form of cancer.” His brother Craig and other family members confirmed he had never been diagnosed with cancer.
Melanotan II is a synthetic analogue of the peptide hormone α-melanocyte-stimulating hormone (α-MSH) that stimulates melanogenesis to facilitate tanning. It may also increase sexual arousal. Melanotan II was originally developed as a tanning agent based on an earlier drug called afamelanotide (previously "Melanotan I") which is now approved by the FDA for the treatment of a particular rare genetic form of sun sensitivity. Melanotan II was later investigated as a potential treatment for sexual dysfunction, but development was abandoned in 2000 in order to pursue development of bremelanotide, a chemically similar drug later approved by the FDA for treatment of sexual dysfunction in women. Unlicensed Melanotan II is found on the internet, although health agencies advise against its use due to legality, case reports suggesting significant safety risks, and potential impurities. Melanotan-II may cause reversible darkening of moles and freckles. It is unclear if Melanotan II can increase (or reduce) the risk of developing melanoma, because reports of melanomas associated with its use have coincided with heavy UV exposure and sun bed use. A 2013 scientific review found there was no conclusive evidence it causes melanoma, and a 2021 review concluded "the increased risk of melanoma in Melanotan users, who use it for tanning and exhibit sun-seeking behaviour, can probably be explained by more UV exposure". Side effects may include facial flushing, nausea and erection in males.
hypotonic Describing a solution containing a low concentration of dissolved solutes relative to another solution, i.e. having negative osmotic pressure, such that solvent will tend to move by osmosis across a semipermeable membrane from the solution of lower solute concentration to the solution of higher concentration until both solutions have equal concentrations. In a cell where the intracellular cytosol is hypotonic relative to the surrounding extracellular fluid (which by definition is hypertonic relative to the cytosol), the solvent (water) will flow across the plasma membrane out of the cytosol, causing the cell to lose water until both sides of the membrane are isotonic. Cells placed in severely hypertonic environments may be at risk of shriveling and desiccating due to the sudden outflow.
β-sheets are formed by H-bonds between an average of 5–10 consecutive amino acids in one portion of the chain with another 5–10 farther down the chain. The interacting regions may be adjacent, with a short loop in between, or far apart, with other structures in between. Every chain may run in the same direction to form a parallel sheet, or in the reverse direction to form an antiparallel sheet, or the chains may form a mixed sheet. The pattern of hydrogen bonding is different in the parallel and antiparallel configurations. Each amino acid in the interior strands of the sheet forms two H-bonds with neighboring amino acids, whereas each amino acid on the outside strands forms only one bond with an interior strand. Looking across the sheet at right angles to the strands, more distant strands are rotated slightly counterclockwise to form a left-handed twist. The Cα-atoms alternate above and below the sheet in a pleated structure, and the R side groups of the amino acids alternate above and below the pleats. The Φ and Ψ angles of the amino acids in sheets vary considerably in one region of the Ramachandran plot. It is more difficult to predict the location of β-sheets than of α-helices. The situation improves somewhat when the amino acid variation in multiple sequence alignments is taken into account.
Sources: en.wikipedia.org
In March 2012, he was asked to head an audit of the UK's industrial performance for Chancellor of the Exchequer George Osborne and HM Treasury, upon which—after 11 years as a member of the House of Lords—he made his maiden speech in the chamber. Heseltine was interviewed in 2012 as part of The History of Parliament's oral history project. In 2023, Heseltine appeared as the guest star in the first episode of The Rest Is Politics: Leading, a podcast hosted by Alastair Campbell and Rory Stewart.
== Transmission == Citrus greening was originally thought to be a viral disease, but is caused by a bacterium, carried by insect vectors. Infection can arise in various climates and is often associated with different species of psyllid insects. For example, citrus crops in Africa become infected under cool conditions as the bacteria are transmitted by the African citrus psyllid Trioza erytreae, an insect that favors cool and moist conditions for optimal activity. Citrus crops in Asia, however, are often infected under warm conditions as the bacteria are transmitted by the Asian citrus psyllid Diaphorina citri. The young larval stage is the most suitable for acquisition of ca. L. asiaticus by the Asian citrus psyllid Diaphorina citri, and some cultivars show greater efficiency in transmitting the disease to the vector than others. Temperature also shows a great influence in the parasite-host relationship between the bacteria and the insect vector, affecting how it is acquired and transmitted by the insects. The causative agents are fastidious phloem-restricted, Gram-negative bacteria in the gracilicutes clade. The Asian form, ca. L. asiaticus is heat tolerant. This means the greening symptoms can develop at temperatures up to 35 °C (95 °F). The African form, ca. L. africanus, and American form, ca. L. americanus, are heat sensitive, thus symptoms only develop when the temperature is in the range 20–25 °C (68–77 °F). Although T. erytreae is the natural vector of African citrus greening and D.
== Role as a cancer promoter == FGF19 is frequently amplified in human cancers. Amplification of the FGF19 genomic locus was found in liver cancer, breast cancer, lung cancer, prostate cancer, bladder cancer, and esophageal cancer, among others. Targeting FGF19 inhibits tumor growth in colon cancer cells and hepatocellar carcinoma. Increase in FGF19 correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
Based on his own experience as a Rhodes Scholar, Florey created a version for European students. The European Studentship scheme provided support for graduates from eleven western European and Scandinavian countries with an annual stipend of £1,100 (equivalent to £16,000 in 2025) for two years. Florey raised the money for nine studentships. Florey did not live to see the first studentship awarded in 1969, and without him additional funding was not forthcoming and the money was exhausted by 1980. By then 76 students had benefited from the scheme, and they had published 15 books and 250 articles in peer-reviewed journals. During his term as provost, there was a major construction program to provide enough accommodation for all undergraduates to be able to spend at least two years in residence. This involved three developments, the largest of which was Florey's personal project: the construction of a new building on the River Cherwell at St Clement's, Oxford. The cost was substantial—the purchase price of the site alone was £500,000 (equivalent to £9,133,000 in 2025)—but Florey was accustomed to raising large sums of money. It was designed by the British architect Sir James Stirling. Florey died the day that construction work was scheduled to begin. When the building was opened in 1971, it was named the Florey Building in his honour. Buildings were also named after Florey in Adelaide, Melbourne, and Canberra, where his refurbished original John Curtin School of Medicine Building was renamed the Florey Building in 2015.
The Swiss company GlycArt Biotechnology developed a system using CHO cells, where the cells were engineered to overexpress an enzyme called GnTIII. The effect of this overexpression is to block the formation of fucosylated oligosaccharides on the expressed antibodies. This technology was first reported in 1999 and was the basis of GlycArt Biotechnology. Roche acquired GlycArt in 2005 in order to acquire technology to afucosylate antibodies. GlycArt Biotechnology had been founded in 2000 as a spin-out company of the Swiss Federal Institute of Technology in Zurich. The first commercial product from the GlycArt acquisition was obinutuzumab, which as Gazyva gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia. Kyowa Hakko Kirin's "Potelligent" platform uses a CHO cell line in which FUT8 has been knocked out, and which produces antibodies with little to no fucose in the Fc region. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform. The Company's technology was first reported in 2004.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
不存在。它是依据 ACTH 的一段序列人工设计的分子，天然蛋白质中找不到与之完全相同的七肽。名称属于研究代号，而非天然物质名。